Basic Information
| LncRNA/CircRNA Name | circMTO1 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Monastrol | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Breast Cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, western blot, RNAi, other |
| Sample | breast cancer cell lines (MDA-MB-231, MCF-7, MDA-MB-453, SKBR-3, T47D and MDA-MB-468) |
| Expression Pattern | up-regulated |
| Function Description | Mechanistic investigations suggested that upregulation of circRNA??TO1 suppressed cell viability, promoted monastrol-induced cell cytotoxicity and reversed monastrol resistance. Subsequently, Eg5 was identified as the functional target of circRNA??TO1, and MTO1 inhibited Eg5 protein level but not mRNA level. By treating with protein synthesis inhibitor cycloheximide (CHX), it was revealed that MTO1 did not affect the protein stability of Eg5. RNA-pull down experiments followed by mass spectrometry revealed that MTO1 interacted with tumor necrosis factor receptor associated factor 4 (TRAF4), and sequester TRAF4 from activating Eg5 translation, thereby inhibiting the Eg5 protein level. |
| Pubmed ID | 30015883 |
| Year | 2018 |
| Title | Circular RNA??TO1 Suppresses Breast Cancer Cell Viability and Reverses Monastrol Resistance Through Regulating the TRAF4/Eg5 Axis |
External Links
| Links for circMTO1 | GenBank HGNC NONCODE |
| Links for Breast Cancer | OMIM COSMIC |